Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Healthcare Disparities | 3 | 2025 | 491 | 1.360 |
Why?
|
| Telemedicine | 2 | 2025 | 229 | 1.300 |
Why?
|
| Neuroblastoma | 6 | 2015 | 400 | 0.970 |
Why?
|
| Compensation and Redress | 4 | 2025 | 27 | 0.900 |
Why?
|
| Cultural Diversity | 1 | 2025 | 68 | 0.870 |
Why?
|
| Crime Victims | 4 | 2025 | 56 | 0.860 |
Why?
|
| Specialties, Surgical | 1 | 2025 | 77 | 0.850 |
Why?
|
| Aurora Kinase A | 2 | 2014 | 15 | 0.840 |
Why?
|
| Pediatrics | 2 | 2025 | 399 | 0.770 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 491 | 0.670 |
Why?
|
| Azepines | 2 | 2015 | 28 | 0.530 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 553 | 0.410 |
Why?
|
| Child | 7 | 2025 | 7625 | 0.380 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 563 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 354 | 0.370 |
Why?
|
| Carcinogenesis | 1 | 2014 | 235 | 0.360 |
Why?
|
| Wounds and Injuries | 2 | 2025 | 283 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 307 | 0.340 |
Why?
|
| Pyrimidines | 1 | 2013 | 386 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 611 | 0.300 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2418 | 0.240 |
Why?
|
| Cholangiography | 1 | 2025 | 38 | 0.230 |
Why?
|
| Biliary Tract Diseases | 1 | 2025 | 37 | 0.230 |
Why?
|
| Sex Offenses | 1 | 2025 | 22 | 0.220 |
Why?
|
| Domestic Violence | 1 | 2025 | 30 | 0.220 |
Why?
|
| Vulnerable Populations | 1 | 2025 | 94 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2015 | 2778 | 0.200 |
Why?
|
| Illinois | 4 | 2025 | 531 | 0.200 |
Why?
|
| Racism | 1 | 2025 | 105 | 0.200 |
Why?
|
| Health Equity | 1 | 2025 | 103 | 0.190 |
Why?
|
| Infant | 2 | 2025 | 3363 | 0.170 |
Why?
|
| Humans | 16 | 2025 | 96105 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 111 | 0.170 |
Why?
|
| Child, Preschool | 2 | 2025 | 3974 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 1346 | 0.160 |
Why?
|
| Chicago | 1 | 2025 | 1506 | 0.160 |
Why?
|
| Duodenostomy | 1 | 2018 | 1 | 0.150 |
Why?
|
| Duodenal Obstruction | 1 | 2018 | 4 | 0.150 |
Why?
|
| Intestinal Atresia | 1 | 2018 | 6 | 0.150 |
Why?
|
| Duodenum | 1 | 2018 | 112 | 0.140 |
Why?
|
| Adolescent | 3 | 2025 | 9895 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2860 | 0.130 |
Why?
|
| Cell Hypoxia | 2 | 2015 | 187 | 0.130 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2013 | 70 | 0.130 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 152 | 0.120 |
Why?
|
| RNA Interference | 2 | 2014 | 385 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2013 | 433 | 0.120 |
Why?
|
| Receptors, Bombesin | 1 | 2015 | 2 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2015 | 403 | 0.110 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2014 | 12 | 0.110 |
Why?
|
| Male | 8 | 2025 | 45863 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 110 | 0.110 |
Why?
|
| Neurogenesis | 1 | 2015 | 90 | 0.110 |
Why?
|
| Glycolysis | 1 | 2015 | 191 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 41 | 0.100 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2013 | 4 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2014 | 280 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 89 | 0.100 |
Why?
|
| Cell Movement | 2 | 2014 | 816 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 149 | 0.090 |
Why?
|
| Transfection | 1 | 2014 | 908 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 367 | 0.090 |
Why?
|
| United States | 1 | 2025 | 7768 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 897 | 0.090 |
Why?
|
| Cell Division | 1 | 2013 | 705 | 0.090 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 1010 | 0.090 |
Why?
|
| Protein Transport | 1 | 2013 | 439 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 465 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1753 | 0.090 |
Why?
|
| Female | 5 | 2025 | 50028 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2025 | 10287 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1756 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 793 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2008 | 144 | 0.060 |
Why?
|
| Laparoscopy | 2 | 2025 | 784 | 0.060 |
Why?
|
| Indocyanine Green | 1 | 2025 | 25 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2025 | 70 | 0.060 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2015 | 40 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2025 | 89 | 0.060 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 65 | 0.050 |
Why?
|
| Homicide | 1 | 2025 | 54 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2025 | 174 | 0.050 |
Why?
|
| Curriculum | 1 | 2008 | 615 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2015 | 830 | 0.050 |
Why?
|
| Middle Aged | 3 | 2025 | 28368 | 0.040 |
Why?
|
| Adult | 3 | 2025 | 28721 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 750 | 0.040 |
Why?
|
| Time Factors | 1 | 2025 | 5580 | 0.030 |
Why?
|
| Antimutagenic Agents | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cobalt | 1 | 2015 | 31 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 325 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 181 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 796 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 170 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 528 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 411 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 256 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 701 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 7025 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 692 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 28891 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 367 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1828 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 555 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 12537 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1562 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1535 | 0.020 |
Why?
|
| Rhode Island | 1 | 2008 | 9 | 0.020 |
Why?
|
| Mentors | 1 | 2008 | 101 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2578 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1670 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 9175 | 0.010 |
Why?
|
| Students, Medical | 1 | 2008 | 455 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 3581 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2008 | 854 | 0.010 |
Why?
|